Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FKKK3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $104,947
Award facts
- Contract value 100% obligated
- $104,947.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at approximately $105K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 mL vials. This firm fixed-price delivery order, awarded on January 7, 2026, with an ultimate completion date of January 29, 2026, was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply across Department of Defense healthcare operations worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status and extensive product portfolio spanning oncology treatments, immunosuppressants, biologics, vaccines, and medical consumables. The company's single-award IDC under the PPV-G GEN V program, valued at $499.9 million with a completion date of December 31, 2036, positions it as a regional prime vendor contractor authorized to supply diverse pharmaceutical products to support recurring military healthcare facility needs globally. The contractor's demonstrated performance across numerous delivery orders and its comprehensive inventory capabilities underscore its role as a key pharmaceutical distributor for Department of Defense operations.
Quick answers
Who was awarded contract SPE2DR26FKKK3?
SPE2DR26FKKK3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26FKKK3 worth?
The government has obligated $104,947 on SPE2DR26FKKK3.
Is contract SPE2DR26FKKK3 an order under another contract?
Yes. SPE2DR26FKKK3 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKK3 competed?
The extent of competition for SPE2DR26FKKK3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award